Individualization of propranolol therapy.

[1]  W. Pettinger,et al.  Minoxidil — An Alternative to Nephrectomy for Refractory Hypertension , 1973 .

[2]  D. Shand,et al.  Disposition of propranolol VI. Independent variation in steady‐state circulating drug concentrations and half‐life as a result of plasma drug binding in man , 1973, Clinical pharmacology and therapeutics.

[3]  D. Shand,et al.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. , 1973, The Journal of pharmacology and experimental therapeutics.

[4]  W. Campbell,et al.  Adrenergic Component of Renin Release Induced by Vasodilating Antihypertensive Drugs in the Rat , 1973, Circulation research.

[5]  C. Dollery,et al.  Central hypotensive effect of propranolol in the rabbit. , 1973, British journal of pharmacology.

[6]  J. Weil,et al.  Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol. , 1973, The Journal of clinical investigation.

[7]  J. Reid,et al.  Mechanism of beta-blockade hypotension. , 1973, The New England journal of medicine.

[8]  J. Laragh,et al.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. , 1972, The New England journal of medicine.

[9]  P. Lockwood,et al.  [Use of propranolol in treatment of hypertension]. , 1972, Revue medicale de Liege.

[10]  J. Vickers,et al.  Propranolol in hypertension: a study of long-term therapy, 1964-1970. , 1972, American heart journal.

[11]  J. Koch-weser,et al.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. , 1972, The New England journal of medicine.

[12]  D. Shand,et al.  Effect of route of administration on the relationship between β‐adrenergic blockade and plasma propranolol level , 1972, Clinical pharmacology and therapeutics.

[13]  A. Michelakis,et al.  The effect of chronic adrenergic receptor blockade on plasma renin activity in man. , 1972, The Journal of clinical endocrinology and metabolism.

[14]  J. Oates,et al.  Hypertrophic obstructive cardiomyopathy in an infant--propranolol therapy for three years. , 1971, The New England journal of medicine.

[15]  J. Fitzgerald,et al.  Pharmacology of 4‐hydroxypropranolol, a metabolite of propranolol , 1971, British journal of pharmacology.

[16]  P. Gillam,et al.  Assessment of propranolol in angina pectoris. Clinical dose response curve and effect on electrocardiogram at rest and on exercise. , 1971, British heart journal.

[17]  D. Shand,et al.  Plasma Propranolol Levels Associated with Suppression of Ventricular Ectopic Beats , 1971, British medical journal.

[18]  D. Shand,et al.  Plasma Propranolol Levels in the Quantitative Assessment of β-adrenergic Blockade in Man , 1970, British medical journal.

[19]  G. Kelliher,et al.  Central hypotensive activity of dl- and d-propranolol. , 1970, Journal of pharmaceutical sciences.

[20]  C. E. Mclean,et al.  Propranolol Dose Determinants Including Blood Level Studies , 1970, Angiology.

[21]  J. Oates,et al.  Plasma propranolol levels in adults With observations in four children , 1970, Clinical pharmacology and therapeutics.

[22]  P. Bond.  Metabolism of Propranolol (‘Inderal’), a Potent, Specific β-Adrenergic Receptor Blocking Agent , 1967, Nature.

[23]  P. Keelan,et al.  Multicenter trial of propranolol in angina pectoris. , 1966, The American journal of cardiology.

[24]  P. Gillam,et al.  Use of Propranolol (Inderal) in Treatment of Hypertension , 1964, British medical journal.

[25]  Shand Dg,et al.  The disposition of propranolol. I. Elimination during oral absorption in man. , 1972 .

[26]  J. Koch-weser,et al.  Relation of Propranolol Plasma Level to β-Blockade during Oral Therapy , 1972 .